HC Wainwright & Co. analyst Andrew Fein maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and raises the price target from $6 to $20.
Syros Pharmaceuticals To Present Initial Data From SELECT-AML-1 Phase 2 Trial At 64th ASH Annual Meeting
November 3, 9:22 AM
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing
October 6, 4:11 PM
October 5, 11:36 AM
Syros Pharmaceuticals's (NASDAQ:SYRS) short percent of float has fallen 48.18% since its last report. The company recently reported that it has 775 thousand shares sold short, which is 4.12% of all regular shares that are available for trading.
October 3, 10:41 AM
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Oct. 3 based on the Fintel short squeeze leaderboard.
September 26, 10:48 AM
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.